Literature DB >> 9174282

Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column.

D A Stopher1, R Gage.   

Abstract

A fully automated method has been developed for the analysis of a new antifungal agent, voriconazole, in human plasma. Multidimensional chromatography was used with size-exclusion chromatography as the first step to separate plasma protein from the drug and internal standard which were then trapped on a precolumn of pellicular ODS. A reversed-phase column, Spherisorb ODS2, then separated drug and internal standard from one another and from remaining plasma components. With an injection of 0.56 ml plasma the limit of quantitation of the method was 5 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174282     DOI: 10.1016/s0378-4347(96)00408-2

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  26 in total

1.  Development and validation of a high-performance liquid chromatography assay for voriconazole.

Authors:  Gennethel J Pennick; Martin Clark; Deanna A Sutton; Michael G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Lynn Purkins; Nolan Wood; Parviz Ghahramani; Diane Kleinermans; Gary Layton; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

3.  Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

Authors:  Thomas J Walsh; Timothy Driscoll; Peter A Milligan; Nolan D Wood; Haran Schlamm; Andreas H Groll; Hasan Jafri; Antonio C Arrieta; Nigel J Klein; Irja Lutsar
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

4.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

5.  Topical voriconazole as a novel treatment for fungal keratitis.

Authors:  William Sponsel; Nancy Chen; Demi Dang; Gianmarco Paris; John Graybill; Laura K Najvar; Lei Zhou; Kwok-Wai Lam; Randolph Glickman; Frank Scribbick
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.

Authors:  Kathrin Kahle; Peter Langmann; Diana Schirmer; Ulrike Lenker; Daniela Keller; Annegret Helle; Hartwig Klinker; Werner J Heinz
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

7.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.

Authors:  Ping Liu; Grover Foster; Robert Labadie; Eugene Somoza; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

9.  Validated LC Method for the Estimation of Voriconazole in Bulk and Formulation.

Authors:  C N Patel; J B Dave; J V Patel; B Panigrahi
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

10.  Development and Validation of Stability Indicating RP-HPLC Method for Voriconazole.

Authors:  A B Khetre; P K Sinha; Mrinalini C Damle; R Mehendre
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.